Apr 02, 2019 · Today, AstraZeneca plc (NYSE:AZN) stock was downgraded by UBS Group from Neutral to Sell with a price target of $40.73. There are 11 Buy Ratings, 3 … AstraZeneca (LON:AZN) price target set to GBX 6,570 by ... Apr 03, 2019 · Today, Kepler Capital Markets set its price target on AstraZeneca (LON:AZN) to GBX 6,570 per share. There are 13 Buy Ratings, 6 Hold Ratings, 3 Sell Ratings, no Strong Buy Ratings on the stock. Oddo Securities Cuts AstraZeneca (LON:AZN) Price Target to ...
See AstraZeneca price target based on 3 analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is $56.50 with a high forecast of $58.00 and a low forecast of $55.00. The average price target represents a 29.05% increase from the last price of $43.78.
Oddo Securities Cuts AstraZeneca (LON:AZN) Price Target to ... 5 days ago · Kepler Capital Markets cut their target price on AstraZeneca from GBX 8,000 ($105.24) to GBX 7,700 ($101.29) and set a buy rating on the stock in a research report on Tuesday, February 18th. Deutsche Bank reissued a buy rating and set a GBX 8,300 ($109.18) target price on shares of AstraZeneca in a research report on Tuesday. AstraZeneca (LON:AZN) Price Target Lowered to GBX 8,000 at ... AstraZeneca (LON:AZN) had its price target cut by analysts at Barclays from GBX 8,500 ($111.81) to GBX 8,000 ($105.24) in a research report issued on Tuesday, ThisIsMoney.Co.Uk reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays Lowers AstraZeneca (LON:AZN) Price Target to GBX ... AstraZeneca (LON:AZN) had its price target dropped by equities research analysts at Barclays from GBX 8,500 ($111.81) to GBX 8,000 ($105.24) in a research report issued to clients and investors on Tuesday, Borsen Zeitung reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock.
Bernstein sees opportunity in a buyout target. AstraZeneca Stock Upgraded: What You Need to Know But is Bernstein right to recommend AstraZeneca? Is the stock's newfound price strength
AZN | AstraZeneca PLC ADR Overview | MarketWatch AstraZeneca said in October that Tagrisso brought in $2.3 billion in sales year-to-date, an 82% jump compared to the year prior. Its stock was up 0.7% on Wednesday. ASTRAZENECA PLC : Target Price Consensus and Analysts ... ASTRAZENECA: Imfinzi approved in the US for extensive-stage small cell lung cancer; Only PD-1/PD-L1 immunotherapy to demonstrate a significant survival benefit in combination with etoposide and a choice of carboplatin or cisplatin chemotherapy AZN | AstraZeneca PLC ADR Analyst Estimates & Rating – WSJ AstraZeneca PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. AZN updated stock price target summary.